
Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.
Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 18, 11, 1, 1, 15, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.
Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 18, 11, 1, 1, 15, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
140 Pages
- Introduction
- Global Markets Direct Report Coverage
- Diabetic Foot Ulcers – Overview
- Diabetic Foot Ulcers – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diabetic Foot Ulcers – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Foot Ulcers – Companies Involved in Therapeutics Development
- Alan Laboratories Inc
- Anterogen Co Ltd
- Aposcience AG
- APstem Therapeutics Inc
- AptaBio Therapeutics Inc
- Asia Stem Cell Regenerative Pharmaceutical Co Ltd
- Aurealis Therapeutics AG
- Beijing Huafeng Biotechnology Co Ltd
- Bio-Bank Corp
- Biofilm Pharma
- BioTissue Inc
- bioXXmed AG
- Blue Blood Biotech Corp
- Canton Biotechnologies Inc
- Cellics Therapeutics Inc
- Cellresearch Corp Pte Ltd
- Chiesi Farmaceutici SpA
- Chrysalis BioTherapeutics Inc
- Crescita Therapeutics Inc
- CSA Biotechnologies LLC
- Cynata Therapeutics Ltd
- Destiny Pharma Plc
- Energenesis Biomedical Co Ltd
- Health & Biotech Co Ltd
- Helixmith Co Ltd
- Hoth Therapeutics Inc
- Lakewood-Amedex Inc
- Madam Therapeutics BV
- Mallinckrodt Plc
- MangoGen Pharma Inc
- MediWound Ltd
- MimeTech Srl-
- Mirae Cell Bio Co Ltd
- NovaLead Pharma Pvt Ltd
- OliX Pharmaceuticals Inc
- Omnio AB
- Perpetuum BV
- Pherecydes Pharma SA
- Promore Pharma AB
- Qilu Pharmaceutical Co Ltd
- Recce Pharmaceuticals Ltd
- Remedor Biomed Ltd
- RHEACELL GmbH & Co KG
- Riptide Bioscience Inc
- SaNOtize Research and Development Corp
- Scarless Laboratories Inc
- Selsym Biotech Inc
- Serodus ASA
- Shionogi & Co Ltd
- Stempeutics Research Pvt Ltd
- TechnoPhage SA
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Topadur Pharma AG
- Transwell Biotech Co Ltd
- Vasomune Inc
- Venturis Therapeutics Inc
- Vitti Labs LLC
- Zhittya Genesis Medicine Inc
- ZZ Biotech LLC
- Diabetic Foot Ulcers – Drug Profiles
- 3K3A-APC – Drug Profile
- Amesanar – Drug Profile
- AP-185 – Drug Profile
- APO-2 – Drug Profile
- ASCP-02 – Drug Profile
- AUP-16 – Drug Profile
- AV-001 – Drug Profile
- BB-101 – Drug Profile
- BFP-001 – Drug Profile
- BFP-101 – Drug Profile
- Biologic for Diabetic Foot Ulcers – Drug Profile
- Cell Therapy for Diabetic Foot Ulcer – Drug Profile
- Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers – Drug Profile
- CHF-6467 – Drug Profile
- Corlicyte – Drug Profile
- CSA-144 – Drug Profile
- CTX-001 – Drug Profile
- CVBT-141 – Drug Profile
- CVBT-141B – Drug Profile
- CYP-006TK – Drug Profile
- diperoxochloric acid – Drug Profile
- donaperminogene seltoplasmid – Drug Profile
- Drug for Diabetic Foot Ulcer – Drug Profile
- ENERGIF-703 – Drug Profile
- Epoetin alfa – Drug Profile
- EscharEx – Drug Profile
- EscharEx Second Generation – Drug Profile
- esmolol hydrochloride – Drug Profile
- exeporfinium chloride – Drug Profile
- FGF-1 – Drug Profile
- Gene Therapy for Diabetic Foot Ulcers and Wound – Drug Profile
- Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers – Drug Profile
- ISN-001 – Drug Profile
- MR-MC-01 – Drug Profile
- MSC Exosomal Topical Suspension – Drug Profile
- MT-003 – Drug Profile
- Mul-1867 – Drug Profile
- NORS-2791 – Drug Profile
- Nu-3 – Drug Profile
- OLX-106 – Drug Profile
- PCSPH-08 – Drug Profile
- PP-2351 – Drug Profile
- RECCE-327 – Drug Profile
- Recombinant Human Platelet-Derived Growth Factor Gel – Drug Profile
- recombinant plasminogen – Drug Profile
- rhPDGF-BB – Drug Profile
- ropocamptide – Drug Profile
- RP-557 – Drug Profile
- rusalatide acetate – Drug Profile
- SER-190 – Drug Profile
- SLIF-06 – Drug Profile
- Small Molecule for Diabetic Foot Ulcers – Drug Profile
- Small Molecule to Inhibit NOX for Diabetic Foot Ulcers – Drug Profile
- Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis – Drug Profile
- Small Molecules for Infected Diabetic Foot Ulcers – Drug Profile
- SR-0379 – Drug Profile
- Stem Cell Therapy for Diabetic Foot Ulcers – Drug Profile
- Stem Cell Therapy for Diabetic Foot Ulcers, Injuries and Liver Diseases – Drug Profile
- Stempeucel – Drug Profile
- suramin – Drug Profile
- SymHeal – Drug Profile
- tobramycin + triclosan – Drug Profile
- TOPN-53 – Drug Profile
- TP-102 – Drug Profile
- TTAX-01 – Drug Profile
- TWB-103 – Drug Profile
- udonitrectag – Drug Profile
- WF-10 – Drug Profile
- Diabetic Foot Ulcers – Dormant Projects
- Diabetic Foot Ulcers – Discontinued Products
- Diabetic Foot Ulcers – Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2022: Recce Pharmaceuticals announces expansion and acceleration of clinical programs
- Sep 26, 2022: CellResearch to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles
- Sep 19, 2022: Ceria Therapeutics awarded a $300,000 SBIR Grant to advance development of a novel treatment of non-healing diabetic foot ulcers
- Sep 16, 2022: CellResearch (CRC) announces positive results of phase I study for CorLiCyte
- Aug 10, 2022: Promore Pharma granted EU patent regarding treatment of chronic wounds
- Jul 07, 2022: Destiny Pharma announces publication of XF-73 drug synergy data
- Apr 21, 2022: Cynata advances clinical trial in Diabetic Foot Ulcers
- Apr 12, 2022: MediWound's EscharEx highlighted in poster and oral presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
- Apr 05, 2022: Lakewood-Amedex enrolls first patient in phase 2 clinical trial for patients with chronic diabetic foot Ulcers (cDFU
- Mar 29, 2022: MediWound to present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
- Dec 22, 2021: Cynata commences DFU clinical trial
- Nov 04, 2021: TechnoPhage announces first clinical safety results with innovative biological product TP-102
- Oct 22, 2021: Helixmith announces phase 3 study results of novel gene therapy treatment for diabetic foot ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer Conference (DFCon)
- Aug 24, 2021: Another take on TP-102 Phase I/IIa Clinical Trial by Jornal Expresso
- Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Diabetic Foot Ulcers, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Universities/Institutes, 2022
- Table 12: Number of Products by Stage and Target, 2022
- Table 13: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Diabetic Foot Ulcers – Pipeline by Alan Laboratories Inc, 2022
- Table 19: Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, 2022
- Table 20: Diabetic Foot Ulcers – Pipeline by Aposcience AG, 2022
- Table 21: Diabetic Foot Ulcers – Pipeline by APstem Therapeutics Inc, 2022
- Table 22: Diabetic Foot Ulcers – Pipeline by AptaBio Therapeutics Inc, 2022
- Table 23: Diabetic Foot Ulcers – Pipeline by Asia Stem Cell Regenerative Pharmaceutical Co Ltd, 2022
- Table 24: Diabetic Foot Ulcers – Pipeline by Aurealis Therapeutics AG, 2022
- Table 25: Diabetic Foot Ulcers – Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2022
- Table 26: Diabetic Foot Ulcers – Pipeline by Bio-Bank Corp, 2022
- Table 27: Diabetic Foot Ulcers – Pipeline by Biofilm Pharma, 2022
- Table 28: Diabetic Foot Ulcers – Pipeline by BioTissue Inc, 2022
- Table 29: Diabetic Foot Ulcers – Pipeline by bioXXmed AG, 2022
- Table 30: Diabetic Foot Ulcers – Pipeline by Blue Blood Biotech Corp, 2022
- Table 31: Diabetic Foot Ulcers – Pipeline by Canton Biotechnologies Inc, 2022
- Table 32: Diabetic Foot Ulcers – Pipeline by Cellics Therapeutics Inc, 2022
- Table 33: Diabetic Foot Ulcers – Pipeline by Cellresearch Corp Pte Ltd, 2022
- Table 34: Diabetic Foot Ulcers – Pipeline by Chiesi Farmaceutici SpA, 2022
- Table 35: Diabetic Foot Ulcers – Pipeline by Chrysalis BioTherapeutics Inc, 2022
- Table 36: Diabetic Foot Ulcers – Pipeline by Crescita Therapeutics Inc, 2022
- Table 37: Diabetic Foot Ulcers – Pipeline by CSA Biotechnologies LLC, 2022
- Table 38: Diabetic Foot Ulcers – Pipeline by Cynata Therapeutics Ltd, 2022
- Table 39: Diabetic Foot Ulcers – Pipeline by Destiny Pharma Plc, 2022
- Table 40: Diabetic Foot Ulcers – Pipeline by Energenesis Biomedical Co Ltd, 2022
- Table 41: Diabetic Foot Ulcers – Pipeline by Health & Biotech Co Ltd, 2022
- Table 42: Diabetic Foot Ulcers – Pipeline by Helixmith Co Ltd, 2022
- Table 43: Diabetic Foot Ulcers – Pipeline by Hoth Therapeutics Inc, 2022
- Table 44: Diabetic Foot Ulcers – Pipeline by Lakewood-Amedex Inc, 2022
- Table 45: Diabetic Foot Ulcers – Pipeline by Madam Therapeutics BV, 2022
- Table 46: Diabetic Foot Ulcers – Pipeline by Mallinckrodt Plc, 2022
- Table 47: Diabetic Foot Ulcers – Pipeline by MangoGen Pharma Inc, 2022
- Table 48: Diabetic Foot Ulcers – Pipeline by MediWound Ltd, 2022
- Table 49: Diabetic Foot Ulcers – Pipeline by MimeTech Srl, 2022
- Table 50: Diabetic Foot Ulcers – Pipeline by Mirae Cell Bio Co Ltd, 2022
- Table 51: Diabetic Foot Ulcers – Pipeline by NovaLead Pharma Pvt Ltd, 2022
- Table 52: Diabetic Foot Ulcers – Pipeline by OliX Pharmaceuticals Inc, 2022
- Table 53: Diabetic Foot Ulcers – Pipeline by Omnio AB, 2022
- Table 54: Diabetic Foot Ulcers – Pipeline by Perpetuum BV, 2022
- Table 55: Diabetic Foot Ulcers – Pipeline by Pherecydes Pharma SA, 2022
- Table 56: Diabetic Foot Ulcers – Pipeline by Promore Pharma AB, 2022
- Table 57: Diabetic Foot Ulcers – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 58: Diabetic Foot Ulcers – Pipeline by Recce Pharmaceuticals Ltd, 2022
- Table 59: Diabetic Foot Ulcers – Pipeline by Remedor Biomed Ltd, 2022
- Table 60: Diabetic Foot Ulcers – Pipeline by RHEACELL GmbH & Co KG, 2022
- Table 61: Diabetic Foot Ulcers – Pipeline by Riptide Bioscience Inc, 2022
- Table 62: Diabetic Foot Ulcers – Pipeline by SaNOtize Research and Development Corp, 2022
- Table 63: Diabetic Foot Ulcers – Pipeline by Scarless Laboratories Inc, 2022
- Table 64: Diabetic Foot Ulcers – Pipeline by Selsym Biotech Inc, 2022
- Table 65: Diabetic Foot Ulcers – Pipeline by Serodus ASA, 2022
- Table 66: Diabetic Foot Ulcers – Pipeline by Shionogi & Co Ltd, 2022
- Table 67: Diabetic Foot Ulcers – Pipeline by Stempeutics Research Pvt Ltd, 2022
- Table 68: Diabetic Foot Ulcers – Pipeline by TechnoPhage SA, 2022
- Table 69: Diabetic Foot Ulcers – Pipeline by TGV-Inhalonix Inc, 2022
- Table 70: Diabetic Foot Ulcers – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
- Table 71: Diabetic Foot Ulcers – Pipeline by Topadur Pharma AG, 2022
- Table 72: Diabetic Foot Ulcers – Pipeline by Transwell Biotech Co Ltd, 2022
- Table 73: Diabetic Foot Ulcers – Pipeline by Vasomune Inc, 2022
- Table 74: Diabetic Foot Ulcers – Pipeline by Venturis Therapeutics Inc, 2022
- Table 75: Diabetic Foot Ulcers – Pipeline by Vitti Labs LLC, 2022
- Table 76: Diabetic Foot Ulcers – Pipeline by Zhittya Genesis Medicine Inc, 2022
- Table 77: Diabetic Foot Ulcers – Pipeline by ZZ Biotech LLC, 2022
- Table 78: Diabetic Foot Ulcers – Dormant Projects, 2022
- Table 79: Diabetic Foot Ulcers – Dormant Projects, 2022 (Contd..1)
- Table 80: Diabetic Foot Ulcers – Dormant Projects, 2022 (Contd..2)
- Table 81: Diabetic Foot Ulcers – Dormant Projects, 2022 (Contd..3)
- Table 82: Diabetic Foot Ulcers – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Diabetic Foot Ulcers, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Top 10 Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Top 10 Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.